Regeneron is conducting a study enrolling male participants with Hemophilia B.

You may help progress the understanding of hemophilia B.

Honey-B aims to evaluate disease characteristics in people with hemophilia B that are receiving FIX prophylaxis.

This website provides information about a study, Honey-B, for boys and men with hemophilia B. Hemophilia B is a rare genetic disease characterized by abnormally low amounts of functional Factor IX (factor nine) protein. Factor IX is a protein made naturally in the body and helps the blood form clots to stop bleeding. FIX is expressed by a gene located on the X-chromosome. Men have only one X-chromosome while women have two X-chromosomes. Because of this, severe hemophilia more often affects men, since they do not have a second copy of the gene. People with moderate and severe hemophilia B have spontaneous bleeding inside their bodies, pain and heavy bleeding after a cut or injury.

This disease affects about 4 in every 100,000 men worldwide, according to the World Federation of Hemophilia (WFH).

Studies help doctors better understand how a disease affects patients and how a potential treatment for the disease works in the body. This study plays an important role in increasing doctors’ understanding of hemophilia B, which may help other people with hemophilia B in the future.

Learn more about Honey-B and see if it may be an option for you or someone you know.

en_CAEnglish (Canada)